We've noticed that you're using an ad blocker

Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.

It's off now Dismiss How do I disable my ad blocker?
❌

How to disable your ad blocker for our site:

Adblock / Adblock Plus
  • Click on the AdBlock / AdBlock Plus icon on the top right of your browser.
  • Click “Don’t run on pages on this domain.” OR “Enabled on this site.”
  • Close this help box and click "It's off now".
Firefox Tracking Prevention
  • If you are Private Browsing in Firefox, "Tracking Protection" may casue the adblock notice to show. It can be temporarily disabled by clicking the "shield" icon in the address bar.
  • Close this help box and click "It's off now".
Ghostery
  • Click the Ghostery icon on your browser.
  • In Ghostery versions < 6.0 click “Whitelist site.” in version 6.0 click “Trust site.”
  • Close this help box and click "It's off now".
uBlock / uBlock Origin
  • Click the uBlock / uBlock Origin icon on your browser.
  • Click the “power” button in the menu that appears to whitelist the current website
  • Close this help box and click "It's off now".
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences

Modern Medicine Network
  • Login
  • Register
Skip to main content
Modern Medicine Network
  • Login
  • Register
Menu
User
Home
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences

SUBSCRIBE: Print / eNewsletter

STI-571 Targets More Advanced-Stage CML and Acute Leukemias

Jul 1, 2000
Volume: 
9
Issue: 
7
  • Leukemia & Lymphoma, Chronic Myeloid Leukemia, Hematologic Malignancies

ASCO—STI-571, an investigational drug that has high activity in
benign-phase chronic myelogenous leukemia (CML), also produces
significant hematologic responses in patients with advanced-stage CML
or acute forms of leukemia, Moshe Talpaz, MD, said at the 36th
annual meeting of the American Society of Clinical Oncology (ASCO) in
New Orleans.

The phase I trial was conducted by Dr. Talpaz, of M.D. Anderson
Cancer Center, in conjunction with Charles Sawyer, MD, of UCLA
Jonsson Cancer Center, and Brian Druker, MD, of Oregon Health
Sciences University.

“STI is very active in inducing hematologic remissions in
chronic-phase patients. I can’t say that we expected to find
responses of the same nature in very advanced disease,” Dr.
Talpaz said in an interview with ONI. “Many of these
patients are heavily pretreated with several different doses, so the
true value of the drug in these situation has to be assessed.”

STI-571, which was developed by Dr. Druker in conjunction with
Novartis Pharmaceuticals, inhibits the enzymatic activity of the
Bcr-Abl protein, and is known as a signal transduction inhibitor
(STI). The abnormal Bcr-Abl protein is found in virtually all CML
patients, and is vital to the survival and proliferation of leukemia
cells. When the protein is blocked, the result is a halt to the
progression of the disease.

The current study included 51 patients (48 evaluable), 33 CML
patients in myeloid blast crisis and 15 patients with CML in lymphoid
blast crisis or Bcr-Abl-positive acute lymphocytic leukemia (ALL).

Patients received STI-571 orally once a day. Equal numbers of
patients were treated with six treatment-dose cohorts, ranging from
300 mg to 800 mg, as these doses had previously shown significant
therapeutic benefit in interferon-refractory, stable-phase CML
patients.

Study Results

Among the 33 patients in myeloid blast crisis treated with STI-571, 9
(27%) achieved a complete remission, defined as the decline of bone
marrow blasts to less than 5%. Another 15 had a partial response
(45%) for a total response rate of more than 70%.

Of the 15 patients with lymphoid acute phase CML or Bcr-Abl-positive
ALL, 9 were complete responders and 2 were partial responders for a
total response rate of 70%. Partial response was defined as
suppression of bone marrow blasts to less than 50%.

“The responses are very surprising, because there is a 70%
response rate for each of the situations.” Dr. Talpaz said.
“It is surprising to us that STI-571 worked at all at that
stage. There are so many genetic evolutions between onset and blast
crisis. At this very advanced stage, the disease can move quickly to
change its genetic presentation and develop resistance, so we thought
that at this stage, the disease would be driven by factors other than treatment.”

 Nevertheless, he said, “STI-571 inhibited Bcr-Abl, and it
was active, even at this very advanced stage.”

Patients had some overall moderate toxicity (nausea and vomiting), he
said. Significant periorbital, facial, and leg edema occurred at
doses of 600 mg or more.

Of the 33 patients with CML in myeloid blast crisis, 6 (20%) achieved
ongoing remissions for a period of 5 months to more than a year. Two
of these patients also achieved a complete cytogenetic remission,
with complete disappearance of the Philadelphia chromosome.

“In the lymphoid blast crisis group, regretfully, 8 of the 9
patients who were complete responders suffered a relapse within 1 to
4 months,” Dr. Talpaz reported. “The response was not
durable, and the results for these patients are somewhat
disappointing.”

The one patient with lymphoid blast crisis who had a sustained
response has been in remission for more than 7 months. “She had
an extramedullary relapse, and ultrasound showed tumors in 5 or 6
sites,” he said. “When she started STI-571, the whole
visible measure of disease disappeared within 1 to 2 weeks.”

Dr. Talpaz commented that blast crisis CML and advanced acute
leukemias are aggressive diseases, “and it shouldn’t
surprise us that, at this particular stage, remissions are
short-lived.”

He pointed out that the short remissions seen in this study “do
not change the STI-571 treatment paradigm, because in the chronic
disease phase, the remissions are very durable. We started work on
this drug in 1998 in chronic-phase patients, and remissions are
ongoing.”

Related Articles

  • BCR-ABL1 Levels Can Predict Sustained Deep Molecular Response in CML
  • Rituximab Does Not Improve Outcomes in Primary CNS Lymphoma
  • Adding Brentuximab to BEACOPP Promising in Relapsed Hodgkin Lymphoma
  • Integrating Genetics, MRD Improves Risk Stratification in Childhood ALL
  • Breast Implants Linked to Anaplastic Large-Cell Lymphoma

Resource Topics rightRail

  • Resource Topics
  • Partner Content
Breast Cancer
Lung Cancer
Prostate Cancer
Colorectal Cancer
Melanoma
Cutaneous T-Cell Lymphomas: Mycosis Fungoides and Sézary Syndrome
3 Keys to Success in the Oncology Care Model

Current Issue

Oncology Vol 32 No 4
Apr 15, 2018 Vol 32 No 4
Digital Edition
Subscribe
Connect with Us
  • Twitter
  • Facebook
  • LinkedIn
  • RSS
Modern Medicine Network
  • Home
  • About Us
  • Advertise
  • Advertiser Terms
  • Privacy statement
  • Terms & Conditions
  • Editorial & Advertising Policy
  • Editorial Board
  • Contact Us
Modern Medicine Network
© UBM 2018, All rights reserved.
Reproduction in whole or in part is prohibited.